Rescue and propagation of fully retargeted oncolytic measles viruses

被引:212
|
作者
Nakamura, T
Peng, KW
Harvey, M
Greiner, S
Lorimer, IAJ
James, CD
Russell, SJ
机构
[1] Mayo Clin Coll Med, Program Mol Med, Rochester, MN 55905 USA
[2] Mayo Clin Coll Med, Dept Lab Med & Pathol, Rochester, MN 55905 USA
[3] Univ Ottawa, Ottawa Hlth Res Inst, Ottawa, ON K1H 8L6, Canada
关键词
D O I
10.1038/nbt1060
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Live attenuated measles viruses of the Edmonston lineage (MV-Edm) have potent anti-tumor activity(1-4) but are not entirely tumor-specific owing to widespread distribution of their native receptors, CD46(5,6) and SLAM(7- 9). We have therefore developed a pseudoreceptor system that allows rescue and propagation of fully retargeted viruses displaying single-chain antibody fragments. Viruses retargeted to tumor-selective CD38, epidermal growth factor receptor (EGFR) or EGFR mutant vIII (EGFRvIII) efficiently entered cells through their respective targeted receptors in vitro and in vivo, but not through CD46 and SLAM. When administered intratumorally or intravenously to mice bearing human CD38 or EGFR-positive human tumor xenografts, the targeted viruses demonstrated specific receptor-mediated anti-tumor activity. These data provide an in vivo demonstration of antibody-directed tumor destruction by retargeted oncolytic viruses.
引用
收藏
页码:209 / 214
页数:6
相关论文
共 50 条
  • [1] Rescue and propagation of fully retargeted oncolytic measles viruses
    Takafumi Nakamura
    Kah-Whye Peng
    Mary Harvey
    Suzanne Greiner
    Ian A J Lorimer
    Charles D James
    Stephen J Russell
    Nature Biotechnology, 2005, 23 : 209 - 214
  • [2] Fully retargeted, myeloma-specific oncolytic measles viruses.
    Nakamura, T
    Hummel, HD
    Harvey, M
    Greiner, S
    Topp, M
    Russell, SJ
    BLOOD, 2005, 106 (11) : 971A - 971A
  • [3] Fully retargeted oncolytic measles virus for multiple myeloma therapy.
    Hummel, Horst D.
    Kuntz, Gaby
    Nakamura, Takafumi
    Greiner, Axel
    Russell, Stephen J.
    Einsele, Hermann
    Topp, Max S.
    BLOOD, 2006, 108 (11) : 465B - 465B
  • [4] Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients
    Bah, Eugene S.
    Nace, Rebecca A.
    Peng, Kah Whye
    Munoz-Alia, Miguel Angel
    Russell, Stephen J.
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (10) : 2057 - 2067
  • [5] Specific elimination of CD133+tumor cells with retargeted oncolytic measles viruses
    Abel, Tobias
    Bach, Patricia
    Hoffmann, Christopher
    Gal, Zoltan
    Braun, Gundula
    Voelker, Iris M.
    Ball, Claudia R.
    Johnston, Ian C. D.
    Lauer, Ulrich M.
    Herold-Mende, Christel
    Muehlebach, Michael D.
    Glimm, Hanno
    Buchholz, Christian J.
    HUMAN GENE THERAPY, 2012, 23 (10) : A90 - A91
  • [6] Antibody neutralization of retargeted measles viruses
    Lech, Patrycja J.
    Pappoe, Roland
    Nakamura, Takafumi
    Russell, Stephen J.
    VIROLOGY, 2014, 454 : 237 - 246
  • [7] Measles to the Rescue: A Review of Oncolytic Measles Virus
    Aref, Sarah
    Bailey, Katharine
    Fielding, Adele
    VIRUSES-BASEL, 2016, 8 (10):
  • [8] Production and purification of oncolytic measles viruses
    Grein, Tanja
    Dieken, Hauke
    Loewe, Daniel
    Salzig, Denise
    Weidner, Tobias
    Czermak, Peter
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 255
  • [9] Oncolytic measles viruses for cancer therapy
    Nakamura, T
    Russell, SJ
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (10) : 1685 - 1692
  • [10] In vivo immunomodulatory effects by uPAR-retargeted oncolytic Measles virus
    Khatwani, Natasha K.
    Jing, Yuqi
    Chavez, Valery
    Merchan, Jaime
    CANCER RESEARCH, 2018, 78 (13)